×
About 7,590 results

ALLMedicine™ Acinetobacter Center

Research & Reviews  2,538 results

Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a p...
https://doi.org/10.1038/s41467-022-31455-5 10.1038/nrmicro1789 10.1128/CMR.00058-07 10.1038/nrmicro.2017.148 10.3389/fmicb.2012.00148 10.1128/AAC.02992-14 10.1126/science.aad6791 10.1038/s41579-018-0070-8 10.1093/emph/eoy005 10.1038/s41591-019-0437-z 10.1093/ofid/ofaa389 10.1146/annurev-med-080219-122208 10.1007/s00705-016-3173-4 10.1128/MMBR.67.1.86-156.2003 10.1016/bs.aivir.2018.09.003 10.1186/s12859-018-2342-8 10.1016/j.jmb.2020.06.013 10.1186/1471-2105-3-12 10.1007/s12551-017-0348-5 10.1073/pnas.1011218107 10.1038/s41598-017-07910-5 10.1016/S0042-6822(03)00123-5 10.1128/AAC.02877-15 10.1038/s41564-020-00830-7 10.1080/22221751.2021.2002671 10.1371/journal.pone.0011720 10.3389/fmicb.2021.739319 10.1038/srep26717 10.1111/eva.12653 10.1073/pnas.1919888117 10.1016/j.cub.2020.07.036 10.12688/wellcomeopenres.14826.1 10.1093/nar/gkz1136 10.1128/JB.00754-13 10.1073/pnas.1104404108 10.1128/jvi.41.1.345-347.1982 10.1038/s41598-018-33800-5 10.1016/j.carres.2019.107774 10.1128/AAC.49.4.1432-1440.2005 10.3389/fmicb.2020.589234 10.1080/21505594.2020.1855912 10.3389/fmicb.2018.03301 10.1038/186819a0 10.1007/978-1-60327-565-1_4 10.1089/cmb.2012.0021 10.1093/nar/gky379 10.1093/nar/27.23.4636 10.1093/dnares/dsn027 10.1093/nar/gkh152 10.1093/nar/gky092 10.1186/1471-2105-10-421 10.1093/bioinformatics/btu031 10.1006/jmbi.2000.4315 10.1371/journal.pone.0011147 10.1093/nar/gkh340 10.1093/nar/gkn180 10.1080/10635150600755453 10.1186/1471-2105-7-439 10.1093/nar/gkz268 10.1371/journal.pcbi.1008214 10.1371/journal.pcbi.1006790 10.1093/nar/gkaa434 10.1186/1471-2105-11-119 10.1038/s41587-019-0100-8 10.1101/gr.1239303 10.1371/journal.pbio.1002342 10.1093/bioinformatics/btt291 10.1093/bioinformatics/btq281 10.1093/bioinformatics/btu170 10.1371/journal.pcbi.1005595 10.1038/nmeth.1923 10.1186/gb-2009-10-3-r25 10.1371/journal.pone.0112963 10.1101/gr.215087.116 10.1093/bioinformatics/btp352 10.1093/nar/gkw569 10.1093/nar/gkw387
Nature Communications; Liu M, Hernandez-Morales A et. al.

Jul 1st, 2022 - In 2016, a 68-year-old patient with a disseminated multidrug-resistant Acinetobacter baumannii infection was successfully treated using lytic bacteriophages. Here we report the genomes of the nine phages used for treatment and three strains of A. ...

Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with...
https://doi.org/10.1186/s12941-022-00523-5 10.3390/pathogens10040387 10.1186/s12941-021-00480-5 10.1186/s12941-022-00492-9 10.1016/j.ijid.2018.11.371 10.1371/journal.pone.0040019 10.1016/j.jim.2021.113169 10.1007/s11033-019-04994-2 10.3390/vaccines9020096 10.1021/acscentsci.0c01621 10.1093/infdis/jiab265 10.1093/infdis/jix315 10.1128/IAI.00162-21 10.1038/s41598-020-79966-9 10.1016/j.vetmic.2012.08.019 10.1016/j.micpath.2017.02.028 10.1371/journal.pone.0029446 10.1186/s12929-020-0617-7 10.1089/mab.2013.0073 10.3390/ijms20246289 10.18502/ijaai.v18i6.2178 10.1007/978-1-4939-2999-3_6 10.1007/s00580-017-2622-0 10.1016/0022-1759(87)90187-6 10.1111/jam.14409 10.1016/j.diagmicrobio.2010.09.008 10.1016/j.pep.2010.11.019 10.1128/JB.00435-12 10.1089/mdr.2020.0505 10.1038/s41598-016-0001-8 10.1186/s12879-020-4811-8 10.1007/s15010-021-01643-4 10.1128/IAI.00741-10 10.3389/fmicb.2019.01379 10.1080/21645515.2015.1052354 10.1007/s10989-017-9665-6 10.1089/mab.2012.0069 10.1186/1471-2180-1-16 10.1128/IAI.00096-09 10.1111/j.1462-5822.2005.00538.x 10.1099/mgen.0.000381 10.3389/fmicb.2020.589234 10.3389/fmicb.2020.589234 10.1007/s00203-021-02343-1 10.1128/IAI.00591-17 10.1128/JB.01416-07 10.1128/IAI.01184-12 10.1007/s12275-021-1394-z
Annals of Clinical Microbiology and Antimicrobials; Yeganeh O, Shabani M et. al.

Jul 1st, 2022 - Acinetobacter baumannii is an opportunistic and antibiotic-resistant pathogen that predominantly causes nosocomial infections. There is urgent need for development nonantibiotic-based treatment strategies. We developed a novel monoclonal antibody ...

A 16S rRNA Sequencing Study Describing the Environmental Microbiota of Two Powdered Inf...
https://doi.org/10.1089/fpd.2021.0116
Foodborne Pathogens and Disease; Cao Y, Macori G et. al.

Jun 30th, 2022 - Microbial safety is critically important for powdered infant formula (PIF) fed to neonates, with under-developed immune systems. The quality and safety of food products are dictated by those microorganisms found in both raw materials and the built...

Risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneum...
https://doi.org/10.1371/journal.pone.0270261
PloS One; Hyun H, Song JY et. al.

Jun 30th, 2022 - Healthcare-associated pneumonia (HCAP) lies in the intersection of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Although HCAP is excluded from the revised HAP guideline, reassessment for HCAP is needed considering its ...

Analysis of environmental driving factors on Core Functional Community during Daqu ferm...
https://doi.org/10.1016/j.foodres.2022.111286
Food Research International (Ottawa, Ont.); Zhu Q, Chen L et. al.

Jun 29th, 2022 - Sauce-flavor Daqu determines the quality of Baijiu because its core functional community (CFC) can produce abundant enzymes and aroma. However, complex environmental factors make it difficult to accurately control the fermentation quality of Daqu....

see more →

Guidelines  3 results

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985752
Antimicrobial Agents and Chemotherapy; Pogue JM, Jones RN et. al.

Nov 27th, 2019 - The polymyxins are important agents for carbapenem-resistant Gram-negative bacilli. The United States Committee on Antimicrobial Susceptibility Testing breakpoint recommendations for colistin and polymyxin B are that isolates of Pseudomonas aerugi...

Task force on management and prevention of Acinetobacter baumannii infections in the ICU.
https://doi.org/10.1007/s00134-015-4079-4
Intensive Care Medicine; Garnacho-Montero J, Dimopoulos G et. al.

Oct 7th, 2015 - Acinetobacter baumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management ...

Preventing catheter-associated urinary tract infections: An executive summary of the As...
https://doi.org/10.1016/j.ajic.2010.08.003
American Journal of Infection Control; Rebmann T, Greene LR

Sep 28th, 2010 - The Association for Professionals in Infection Control and Epidemiology (APIC) began publishing their series of Elimination Guides in 2007. Since then, 9 Elimination Guides have been developed that cover a range of important infection prevention i...

see more →

Drugs  302 results see all →

Clinicaltrials.gov  71 results

Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
https://clinicaltrials.gov/ct2/show/NCT04803708

Jun 21st, 2022 - The primary objective of this study is to evaluate the safety of a topical bacteriophage cocktail in the treatment of non infected and infected diabetic foot ulcers with Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumanni. ...

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI
https://clinicaltrials.gov/ct2/show/NCT03869437

Jun 6th, 2022 - Infections with antibiotic resistant bacteria cause a significant burden of disease worldwide. Bloodstream infections may arise from a variety of sources, are commonly encountered in clinical practice, and are associated with significant morbidity...

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
https://clinicaltrials.gov/ct2/show/NCT04380207

Apr 20th, 2022 - The Centers for Disease Control (CDC) has listed carbapenem-resistant Enterobacteriaceae and Acinetobacter as urgent threats and multidrug resistant Pseudomonas, and extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae as serious t...

Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection
https://clinicaltrials.gov/ct2/show/NCT03349268

Mar 14th, 2022 - In 2011, 721,800 healthcare-associated infections (HAIs) were reported in the United States. The hospital environment has been increasingly recognized as an important determinant of HAI acquisition and prevention of HAIs has become a top priority ...

Infection Control Program in Tracheostomized Patients
https://clinicaltrials.gov/ct2/show/NCT05113329

Mar 3rd, 2022 - Healthcare-associated infections (HAIs) are infections that patients acquire during the course of receiving treatment for other conditions within a healthcare setting and are not present or incubating at the time of admission. Medical instrumentat...

see more →

News  122 results

CDC Details Deadly Aromatherapy Outbreak
https://www.medpagetoday.com/primarycare/generalprimarycare/97467

Mar 2nd, 2022 - While the lavender-scented spritz from Walmart might have seemed the furthest thing from exotic, the Burkholderia pseudomallei bacteria inside sparked a deadly melioidosis outbreak that CDC scientists highlighted as a reason to watch for unexpecte...

Can Phages Help Where Antibiotics Have Failed?
https://www.medscape.com/viewarticle/969001

Feb 23rd, 2022 - A new film called Salt in My Soul was recently released, with one of the expressed goals being to raise funds for phage research and antibiotic resistance. Mallory Smith The film shares the story of Mallory Smith, a young woman, now deceased, who ...

FDA Approval Insights: Daratumumab / Carfilzomib / Dexamethasone in Myeloma
https://www.onclive.com/view/fda-approval-insights-daratumumab-carfilzomib-dexamethasone-in-myeloma

Aug 17th, 2021 - Welcome to OncLive On Air™! I’m your host today, Jessica Hergert. OncLive On Air™ is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital an...

CDC Doc Addresses Today's Pandemic and the Next
https://www.medscape.com/viewarticle/941169

Nov 23rd, 2020 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. On July 1, 2020, when I began a rotation on the infectious disease consult service at the Veterans Administration Hospital in Atlanta, we had three patients with...

FDA Approves Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma
https://www.onclive.com/view/fda-approves-daratumumab-plus-carfilzomib-dexamethasone-in-relapsed-refractory-myeloma

Aug 21st, 2020 - The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (KdD) for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.1 We...

see more →